Abstract
The blood-brain barrier (BBB), a dynamic and complex barrier formed by endothelial cells, can impede the entry of unwanted substances – pathogens and therapeutic molecules alike – into the central nervous system (CNS) from the blood circulation. Taking into account the fact that CNS-related diseases are the largest and fastest growing unmet medical concern, many potential protein- and nucleic acid-based medicines have been developed for therapeutic purposes. However, due to their poor ability to cross the BBB and the plasma membrane, the above-mentioned bio-macromolecules have limited use in treating neurological diseases. Finding effective, safe, and convenient ways to deliver therapeutic molecules into the CNS is thus urgently required. In recent decades, much effort has been expended in the development of drug delivery technologies, of which cell-penetrating peptides (CPPs) have the most promising potential. The present review covers the latest advances in CPP delivery technology, and provides an update on their use in CNS-targeted drug delivery.
Keywords: Central nervous system, blood-brain barrier, cell-penetrating peptides, drug delivery
Current Neuropharmacology
Title:Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Volume: 11 Issue: 2
Author(s): Li-Li Zou, Jie-Lan Ma, Tao Wang, Tang-Bin Yang and Chang-Bai Liu
Affiliation:
Keywords: Central nervous system, blood-brain barrier, cell-penetrating peptides, drug delivery
Abstract: The blood-brain barrier (BBB), a dynamic and complex barrier formed by endothelial cells, can impede the entry of unwanted substances – pathogens and therapeutic molecules alike – into the central nervous system (CNS) from the blood circulation. Taking into account the fact that CNS-related diseases are the largest and fastest growing unmet medical concern, many potential protein- and nucleic acid-based medicines have been developed for therapeutic purposes. However, due to their poor ability to cross the BBB and the plasma membrane, the above-mentioned bio-macromolecules have limited use in treating neurological diseases. Finding effective, safe, and convenient ways to deliver therapeutic molecules into the CNS is thus urgently required. In recent decades, much effort has been expended in the development of drug delivery technologies, of which cell-penetrating peptides (CPPs) have the most promising potential. The present review covers the latest advances in CPP delivery technology, and provides an update on their use in CNS-targeted drug delivery.
Export Options
About this article
Cite this article as:
Zou Li-Li, Ma Jie-Lan, Wang Tao, Yang Tang-Bin and Liu Chang-Bai, Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020006
DOI https://dx.doi.org/10.2174/1570159X11311020006 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies
Current Cancer Therapy Reviews Editorial (Thematic Issue: Mechanisms of Cancer Stem Cell Resistance to Chemotherapy)
Current Signal Transduction Therapy Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Ligand Conjugated Targeted Nanotherapeutics for Treatment of Neurological Disorders
Current Pharmaceutical Design Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Use of Carbohydrate-Conjugated Nanoparticles for an Integrated Approach to Functional Imaging of Glycans and Understanding of their Molecular Mechanisms
Current Pharmaceutical Biotechnology Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders